

ongoing trials - trial from www.clinicaltrials.gov

GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance - Phase 2 - Not yet recruiting

Code: NCT04731272 **Year:** 2021 **Date:** April 1, 2021

Author: University of Pennsylvania|Children's Hospital of Philadelphia

Study design (if review, criteria of inclusion for studies)

Interventional - Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other

Participants

Cystic Fibrosis|Pancreatic Insufficiency|Abnormal Glucose Tolerance|Diabetes - 18 Years and older (Adult, Older Adult)

Interventions

Drug: Dulaglutide 0.75Mg/0.5Ml Inj Pen

Outcome measures

Early-phase insulin secretion|Early-phase insulin secretion adjusted for glucose excursion|Glucose tolerance

<https://ClinicalTrials.gov/show/NCT04731272>

Keywords

Adult; Child; Diabetes Mellitus; Gastrointestinal Diseases; Glucose Intolerance; Hypoglycemic Agents; Pancreatic Diseases; pharmacological_intervention; GLP-1 agonists; dulaglutide;